Want to see ICCC full AI Analyst Report?
Immucell (ICCC) Stock Statistics & Valuation Metrics
Total Valuation
Immucell has a market cap or net worth of $95.91M. The enterprise value is $95.94M.
- Market Cap
- $95.91M
- Enterprise Value
- $95.94M
Share Statistics
Immucell has 9,082,197 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 9,082,197
- Owned by Insiders
- 4.07%
- Owned by Institutions
- 7.86%
Financial Efficiency
Immucell’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is 4.10%.
- Return on Equity (ROE)
- -0.04
- Return on Assets (ROA)
- -0.02
- Return on Invested Capital (ROIC)
- 4.10%
- Return on Capital Employed (ROCE)
- 0.04
- Revenue Per Employee
- 378.69K
- Profits Per Employee
- -14.25K
- Employee Count
- 73
- Asset Turnover
- 0.65
- Inventory Turnover
- 1.75
Valuation Ratios
The current PE Ratio of Immucell is 121.16. Immucell’s PEG ratio is -0.31.
- PE Ratio
- 121.16
- PS Ratio
- 3.03
- PB Ratio
- 2.96
- Price to FCF
- 22.09
- Price to Operating Cash Flow
- 15.77
- PEG Ratio
- -0.31
Income Statement
In the last 12 months, Immucell had revenue of 27.64M and earned -1.04M in profits. Earnings per share was -0.12.
- Revenue
- 27.64M
- Gross Profit
- 11.45M
- Operating Income
- 1.65M
- Pretax Income
- -1.03M
- Net Income
- -1.04M
- EBITDA
- 2.14M
- Earnings Per Share (EPS)
- -0.12
Cash Flow
In the last 12 months, operating cash flow was 5.89M and capital expenditures -1.68M, giving a free cash flow of 4.21M billion.
- Operating Cash Flow
- 5.89M
- Free Cash Flow
- 4.21M
- Free Cash Flow per Share
- 0.46
Dividends & Yields
Immucell pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 4.53%
- Earnings Yield
- 0.85%
Stock Price Statistics
- Beta
- -0.00
- 52-Week Price Change
- 65.06%
- 50-Day Moving Average
- 10.04
- 200-Day Moving Average
- 8.90
- Relative Strength Index (RSI)
- 49.76
- Average Volume (3m)
- 17.52K
Important Dates
Immucell upcoming earnings date is Nov 12, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Immucell as a current ratio of 4.26, with Debt / Equity ratio of 48.77%
- Current Ratio
- 4.26
- Quick Ratio
- 1.93
- Debt to Market Cap
- 0.16
- Net Debt to EBITDA
- 4.39
- Interest Coverage Ratio
- 3.76
Taxes
In the past 12 months, Immucell has paid 11.57K in taxes.
- Income Tax
- 11.57K
- Effective Tax Rate
- -0.01
Enterprise Valuation
Immucell EV to EBITDA ratio is 27.35, with an EV/FCF ratio of 22.95.
- EV to Sales
- 3.15
- EV to EBITDA
- 27.35
- EV to Free Cash Flow
- 22.95
- EV to Operating Cash Flow
- 16.41
Balance Sheet
Immucell has $8.86M in cash and marketable securities with $12.45M in debt, giving a net cash position of -$3.59M billion.
- Cash & Marketable Securities
- $8.86M
- Total Debt
- $12.45M
- Net Cash
- -$3.59M
- Net Cash Per Share
- -$0.39
- Tangible Book Value Per Share
- $3.45
Margins
Gross margin is 40.32%, with operating margin of 12.60%, and net profit margin of 2.57%.
- Gross Margin
- 40.32%
- Operating Margin
- 12.60%
- Pretax Margin
- 2.78%
- Net Profit Margin
- 2.57%
- EBITDA Margin
- 11.53%
- EBIT Margin
- 3.76%
Analyst Forecast
The average price target for Immucell is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 8.49%
- EPS Growth Forecast
- -54.03%
Scores
- Smart Score
- 5
- AI Score
- 67
